Cedilla Therapeutics, an oncology biotech founded by a former Editas executive, has snagged an additional $25 million to bring two small-molecule oncology programs into human trials.. The ...

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in... Contact Us. Contact Us.

About Cedilla’s CDK2 Program CDK2 (cyclin dependent kinase 2) has been a major target of interest for cancer indications driven by amplification or high levels of Cyclin E, including in roughly ...

Third Rock-founded Cedilla launches with $56.2 million to tackle protein stability The biotech firm will first go after tough oncology drug targets by Lisa M. Jarvis ...

Cedilla Therapeutics launched Tuesday with a $56 million investment from Third Rock and a mission to develop small molecules that target the stability of cancer-driving proteins. Others have ...

Cedilla is also eligible to receive tiered royalty payments from Bayer on medicines based on the former’s technology commercialized by Bayer. In the year so far, shares of BAYRY have gained 8.7% ...